Association between Microalbuminuria and MYH9 Gene Polymorphisms in Hypertensive Iraqi Patients with Metabolic Syndrome
DOI:
https://doi.org/10.22317/jcms.v7i2.963Keywords:
Metabolic syndrome, Albumins, MYH9, genotype, ARMS-PCRAbstract
Objective The presented work aimed to study the correlation between microalbuminuria and MYH9 (T>C) (rs3752462) gene polymorphisms in metabolic syndrome of Iraqi patients.
Methods This study was a cross-sectional study. Sample size was 140 persons of both gender selected randomly between April 1, 2019 and Aug. 15, 2020. They are divided into two groups, 80 with metabolic syndrome patients and 60 with control groups subdivided into another two groups: 30 persons with obese and 30 persons without obese. The distribution of sample according to the gender, the number of males had metabolic syndrome were 47 and female 33, but in obese healthy control the number of males were 19 and female 11, while in non-obese healthy control the number of males were 15 and female 15. The age groups were ranged between 40 and 60 years.
Typing of MYH9 was performed by refractory mutation system-polymerase chain reaction (ARMS-PCR). The current study was performed to investigate the SNPs that affected MYH9 gene which was (T>C) (rs3752462).
Results There was a significant difference between blood sugar, HbA1c, total cholesterol, TG, VLDL-C, LDL-C, blood urea, microalbuminuria, BMI, and HOMA-IR in metabolic syndrome patients as compared with healthy control groups (P ≤ 0.01). The significant result (P ≤ 0.01) were appeared between TT for MYH9 genotype patients and obese control with biochemical parameters (Blood glucose, HbA1c, TC, TG, VLDL-C, and LDL-C). The correlation between TT SNP for MYH9 genotype patients and non-obese control with biochemical parameters is significant result (P ≤ 0.01 and P ≤ 0.05) (Blood glucose, HbA1c, insulin, TC, TG, VLDL-C, LDL-C, urea, and microalbuminuria). The significant result (P ≤ 0.01 and P ≤ 0.05) appeared between CT for MYH9 genotype patients and obese control with biochemical parameters (Blood glucose, HbA1c, TC, TG, and VLDL-C) respectively.
Conclusions There is a significant difference between blood glucose, HbA1c, total cholesterol, TG, VLDL-C, LDL-C, blood urea,
microalbuminuria, BMI, and HOMA-IR in metabolic syndrome patients and healthy control groups (P ≤ 0.01). Also, a significant result (P ≤ 0.01) obtained between TT for MYH9 genotype patients and obese and non-obese control with some biochemical parameters. (P ≤ 0.01 and P ≤ 0.05). The significant results (P ≤ 0.01 and P ≤ 0.05) appear between CT for MYH9 genotype patients and obese control with some biochemical parameters.
References
Grundy, SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol, 2006;47.6:1093-1100.
Grundy SM. Does a diagnosis of metabolic syndrome have value in clinical practice? June 2006;83(6).
Grundy, SM. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat Rev Drug Discov, 2006;5.4:295-309.4.
Moller, DE, Kaufman, K D. Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med, 2005;56:45-62.
Eckel, RH., et al. The metabolic syndrome. The Lancet, 2010;375.9710:181-183.
Lakka, H-M, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. Jama, 2002;288.21:2709-2716.
Hunt, Kelly, et al. NCEP versus WHO metabolic syndrome in relation to all cause and cardiovascular mortality in the San Antonio Heart Study (SAHS). Diabetes, 2003;52.
Hansen, ML, Gunn, PW, Kaelber, DC. Underdiagnosis of hypertension in children and adolescents. Jama, 2007;298.8:874-879.
American Diabetes Association, et al. Standards of medical care in diabetes—2010. Diabetes Care, 2010;33(1):S11-S61.
Baynes, HW. Classification, pathophysiology, diagnosis and management of diabetes mellitus. J Diabe Metab, 2015;6.5:1-9.
Chobanian, AV. National heart, lung, and blood institute joint national committee on prevention, detection, evaluation, and treatment of high blood pressure; national high blood pressure education progracoordinating committee: the seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. Jama, 2003;289:2560-2572.
Arrondel, Christelle, et al. Expression of the nonmuscle myosin heavy chain IIA in the human kidney and screening for MYH9 mutations in Epstein and Fechtner syndromes. J Am Soc Nephrol, 2002;13.1:65-74.
Marini MBM, Pecci A, Romagnoli R, Musante L, Candiano G, Ghiggeri GM, Balduini C, Seri M, Marini M, Bruschi M, Pecci A, Romagnoli R, Musante L, Candiano G, Ghiggeri GM, Balduini C, Seri M,Marini M, Bruschi M, Pecci A, Romagnoli R, Musante LC, Non-muscle myosin heavy chain iia and iib interact and co-localize in living cells: Relevance for myh9-related disease. 2016;41(6).
Cheng, Wenrong, et al. Polymorphisms in the nonmuscle myosin heavy chain 9 gene (MYH9) are associated with the progression of IgA nephropathy in Chinese. Nephrol Dial Transplant, 2011;26.8:2544-2549.
Behar, DM., et al. African ancestry allelic variation at the MYH9 gene contributes to increased susceptibility to non-diabetic end-stage kidney disease in Hispanic Americans. Human Mol Genet, 2010;19.9:1816-1827.
Pattaro, Cristian, et al. Genome-wide linkage analysis of serum creatinine in three isolated European populations. Kidney Int, 2009;76.3:297-306.
Kopp, Jeffrey B., et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet, 2008;40.10:1175-1184.
Liu, Liping, et al. Association of MYH9 polymorphisms with hypertension in patients with chronic kidney disease in China. Kidney Blood Press Res, 2016;41.6:956-965.
Freedman, BI., et al. The non-muscle Myosin heavy chain 9 gene (MYH9) is not associated with lupus nephritis in African Americans. Am J Nephrol, 2010;32.1:66-72.
Lipkowitz, MS, et al. Association analysis of the non-muscle myosin heavy chain 9 gene (MYH9) in hypertensive nephropathy: African American Study of Kidney Disease and Hypertension (AASK). J Am Soc Nephrol, 2009;20:56A.
Palaniappan, L, Carnethon, M, Fortmann, SP. Association between microalbuminuria and the metabolic syndrome: NHANES III. Am J
Hypertension, 2003;16.11:952-958.
Kaur, J. Assessment and screening of the risk factors in metabolic syndrome. Med Sci, 2014;2.3:140-152.
Katzmarzyk, PT., et al. Targeting the metabolic syndrome with exercise: evidence from the HERITAGE Family Study. Med Sci Sports Exercise, 2003;35.10:1703-1709.
Bahreinian, Maryam, and Ahmad Esmaillzadeh. “Opinion: quantity and quality of carbohydrate intake in Iran: a target for nutritional intervention.”(2012): 648-649.
Tabatabaei-Malazy O, Qorbani M, Samavat T, Sharifi F, Larijani B, Fakhrzadeh H. Prevalence of dyslipidemia in Iran: a systematic review and meta-analysis study. Int J Prev Med. 2014;5(4):373.
Nelson ME, Rejeski WJ, Blair SN, Duncan PW, Judge JO, King AC, et al. Physical activity and public health in older adults: recommendation from the American College of Sports Medicine and the American Heart Association. Med Sci Sports Exercise. 2007;39(8):1435-45.
Koochek A, Johansson S, Kocturk T, Sundquist J, Sundquist K. Physical activity and body mass index in elderly Iranians in Sweden: a population-based study. Eur J Clin Nutr. 2008;62(11):1326-32.
Simoes EJ, Kobau R, Kapp J, Waterman B, Mokdad A, Anderson L. Associations of physical activity and body mass index with activities of daily living in older adults. J Commun Health. 2006;31(6):453-67.
Bayram F, Kocer D, Gundogan K, Kaya A, Demir O, Coskun R, et al. Prevalence of dyslipidemia and associated risk factors in Turkish adults. J Clin Lipidol. 2014;8(2):206-16.
Karpov Y, Khomitskaya Y. PROMETHEUS: an observational, cross-sectional, retrospective study of hypertriglyceridemia in Russia. Cardiovasc Diabetol. 2015;14(1):115.
Abujbara M, Batieha A, Khader Y, Jaddou H, El-Khateeb M, Ajlouni K. The prevalence of dyslipidemia among Jordanians. J Lipids. 2018;2018.
Penesova A, Cizmarova E, Belan V, Blazicek P, Imrich R, Vlcek M, et al. Insulin resistance in young, lean male subjects with essential hypertension. J Human Hypertension. 2011;25(6):391-400.
Sinha S, Qazi SA, Banik S, Islam MZ. Correlation study of insulin resistance and essential hypertension among Bangladeshi male volunteers. J Young Pharm. 2015;7(3):200.
Sarafidis P, Lasaridis A, Nilsson P, Pikilidou M, Stafilas P, Kanaki A, et al. Validity and reproducibility of HOMA-IR, 1/HOMA-IR, QUICKI and McAuley’s indices in patients with hypertension and type II diabetes. J Human Hypertension. 2007;21(9):709-16.
Schillaci G, Reboldi G, Verdecchia P. High-normal serum creatinine concentration is a predictor of cardiovascular risk in essential hypertension. Arch Intern Med. 2001;161(6):886-91.
Kumar A, Rekha N, Raghav ED. A Study of microalbuminuria in patients with essential hypertension. Int J Contemp Med Res. 2016.
Liu L, Wang C, Mi Y, Liu D, Li L, Fan J, et al. Association of myh9 polymorphisms with hypertension in patients with chronic kidney disease in china. Kidney Blood Pressure Res. 2016;41(6):956-65.
Masconi K. The occurance of genetic variations in the MYH9 gene and their association with CKD in a mixed South African population: Stellenbosch: Stellenbosch University; 2012.
Bondzie PA. New insights into the molecular regulation of kidney disease: contributions of APOL1 and MYH9: Boston University; 2014.
Zhao H, Ma L, Yan M, Wang Y, Zhao T, Zhang H, et al. Association between MYH9 and APOL1 gene polymorphisms and the risk of diabetic kidney disease in patients with Type 2 diabetes in a Chinese Han population. J Diab Res. 2018;2018.
Ling C, Cai C, Chang B, Shi W, Wei F, Yu P, et al. MYH9 gene polymorphisms may be associated with cerebrovascular blood flow in patients with type 2 diabetes. Genet Mol Res. 2015;14(1):1008-16.
Franceschini N, Voruganti VS, Haack K, Almasy L, Laston S, Göring HH, et al. The association of the MYH9 gene and kidney outcomes in American Indians: the Strong Heart Family Study. Human Genet. 2010;127(3):295-301.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Journal of Contemporary Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
